Find your path to Andrew
357 people in our graph share verified history with Andrew — schools, employers, funds. One of them is your warm intro.
Eric WagnerunlockedAndrew: together at The University of North Carolina at Chapel Hill (1990–1993)
×4Andrew: together at AstraZeneca
Andrew: together at The University of North Carolina at Chapel Hill
Andrew: together at Markey Cancer Center, University of Kentucky
About
Andrew Pierce is Chief Scientific Officer at Refoxy Pharma, with more than 20 years in oncology drug development across large pharma and biotech. At Owkin, he established the clinical development function and advanced the company's first asset into Phase 1 across three continents in 16 months, and he previously led translational strategy across oncology portfolios at AstraZeneca. He has served as a national advisor to the UK Medical Research Council and the National Cancer Institute, and his work has included integrating AI into patient selection, biomarker strategy, and trial design.
Chief Science Officer at Refoxy
Intro paths
→
In turn, Andrew can intro founders to Refoxy's investors below.
Refoxy's investors · 4
Co-founders at Refoxy
VB
Victor BustosCo-Founder & CEO
WL
Wolfgang LinkScientific Co-founder & Advisor
Experience
- Refoxy PharmaChief Scientific Officercurrent2026 — presentUnited Kingdom
- Paralog LtdDirectorcurrent2026 — present
- OwkinSenior Vice President - Discovery & Development2024 — 2026United Kingdom
- Crescendo Biologics LimitedVice President - Translational Biology2020 — 2024Cambridge
- AstraZenecaAssociate Director - Translational Medicine Oncology2014 — 2020Cambridge
- MedImmuneSenior Scientist - Translational Medicine Oncology2011 — 2014Gaithersburg, MD
- N-of-One TherapeuticsOncology Biomarker Analyst2010 — 2011Greater Boston
- Markey Cancer Center, University of KentuckyAssistant Professor2003 — 2011Greater Lexington Area
- Memorial Sloan-Kettering Cancer CenterSenior Postdoctoral Research Associate1997 — 2003Greater New York City Area
- Duke UniversityPostdoctoral Research Associate1995 — 1997Raleigh-Durham, North Carolina Area
Skills & more
Investigational New Drug Application (IND)First in Human Studies2AI in Drug Development2Biotechnology14Translational Medicine1Drug Development8Oncology7Clinical Development5
From Andrew's professional profile.
Frequently asked questions
- Who is Andrew Pierce?
- Andrew Pierce is Chief Scientific Officer at Refoxy Pharma, with more than 20 years in oncology drug development across large pharma and biotech. At Owkin, he established the clinical development function and advanced the company's first asset into Phase 1 across three continents in 16 months, and he previously led translational strategy across oncology portfolios at AstraZeneca. He has served as a national advisor to the UK Medical Research Council and the National Cancer Institute, and his work has included integrating AI into patient selection, biomarker strategy, and trial design.
- Where does Andrew Pierce work?
- Andrew Pierce is Chief Science Officer at Refoxy.
- Where did Andrew Pierce go to school?
- Andrew Pierce studied at The University of North Carolina at Chapel Hill (Ph.D., molecular genetics); University of Toronto - University of Trinity College (B.Sc. (honors), Molecular and Cellular Biology).
Same school
Also attended The University of North Carolina at Chapel Hill491
Clint MyersInvestor at RevolutionMahati SridharPartner, Rise of the Rest at RevolutionEric WagnerVP of Research and Data at Redpoint VenturesSoul DayanInvestor at True VenturesAlex LimInvestor at IVP (Institutional Venture Partners)Alex TaubPrincipal at QED Investors
+ 485 more
Also attended University of Toronto - University of Trinity College19
Min TeoManaging Partner & Co-CIO at Ethereal Ventures Management Ltd.John GreenwoodPartner at Pantheon VenturesJoseph MocanuFounder of Verge HealthTech Fund, an early-stage healthtech venture capital fund investing globallyLeila MartinSenior Associate at ACTIVATE CAPITAL PARTNERSMuhammad AbdiInvestor at TorQuest PartnersCiara SalloumInvestor at Clairvest Group Inc
+ 13 more
Shared employers
Also worked at Owkin14
Alex PasteurPartner at F-Prime Capital PartnersSam Smith-EppsteinerPartner at Innovation EndeavorsBruno RaillardCo-Founder and Partner at FrstPierre EntremontCo-Founder and Partner at FrstAdam GhobarahFounder and Managing Partner at Top Harvest CapitalNicole JunkermannFounder at NJF Capital
+ 8 more
Also worked at AstraZeneca159
Detlev BiniszkiewiczManaging Director at MPM BioImpactBriggs MorrisonEntrepreneur Partner at MPM BioImpactJung Lee, PhDVenture Partner at Adelphi Ventures Management, LlcJohan LundVenture Partner at ScietyIliam BarkinoInvestor at IndustrifondenSara JawadInvestor at Industrifonden
+ 153 more
Also worked at Markey Cancer Center, University of Kentucky19
Bobby RileyPlatform Manager at Keyhorse CapitalAutumn RiceDirector of Operations at Keyhorse CapitalCooper WinrichAssociate at FINTOP CapitalIva MatasićVenture Ambassador at Brain-Too-Free VenturesNate MorrisFounder, Chairman & CEO at Morris IndustriesBranden Rosenhan, MDFounding Partner at MedMountain Ventures
+ 13 more
Also worked at Memorial Sloan-Kettering Cancer Center68
Neil NagVenture Partner at Moment Ventures, LlcBridget Martell MA, MDSenior Biopharmaceutical Advisor at Two Bear CapitalTarek El-SawyVenture Partner at RaivenStella PaffenholzSenior Associate at Atlas VentureMaurizio FazioPrincipal at Atlas VentureAlley (Welsh) OlshanskyAdvisor at Casdin Capital
+ 62 more